The study compared the effectiveness of sequential administration of ganciclovir and acyclovir with acyclovir alone in 170 patients followed for one year.
Fungal infections are another common complication of transplant patients.
The study, which involved patients at Mayo Clinic and the University of Nebraska Medical Center, Omaha, was published in the July 15 issue of Transplantation. Promising New Molecular Targets Found for New Therapies Rapamycin is a new drug that holds great promise for fighting organ rejection in transplant patients and tumors in cancer patients. Mayo researchers investigating how the drug works have discovered a new set of molecular targets for new therapies. Rapamycin was originally isolated from a strain of bacteria found in a soil sample collected from the Easter Islands. Studies showed it to be a potent suppressor of the immune system.